We are live on
!
Find out more
KAM
Krensavage Asset Management Portfolio holdings
AUM
$256M
1-Year Est. Return
69.63%
This Fund
S&P 500
This Quarter
Est. Return
+9%
1 Year Est. Return
+69.63%
3 Year Est. Return
+113.28%
5 Year Est. Return
+196.5%
10 Year Est. Return
+463.27%
AUM
$392M
AUM Growth
-$20.6M
(-5%)
Cap. Flow
-$51.4M
Cap. Flow
% of AUM
-13.12%
Top 10 Holdings %
Top 10 Hldgs %
92.28%
Holding
16
New
–
Increased
5
Reduced
9
Closed
2
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
McKesson
MCK
|
+$4.8M |
| 2 |
SHPG
Shire pic
SHPG
|
+$3.67M |
| 3 |
Orthofix Medical
OFIX
|
+$1.88M |
| 4 |
Gilead Sciences
GILD
|
+$781K |
| 5 |
SRGA
Surgalign Holdings, Inc. Common Stock
SRGA
|
+$476K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Enanta Pharmaceuticals
ENTA
|
+$22M |
| 2 |
AVNS
Avanos Medical
AVNS
|
+$11.6M |
| 3 |
United Therapeutics
UTHR
|
+$11.2M |
| 4 |
CONMED
CNMD
|
+$10.4M |
| 5 |
Amgen
AMGN
|
+$3.08M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 90.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
United Therapeutics
UTHR
$25.8B
| $62.5M | 15.95% |
552,019
-101,768
| -16% | -$11.2M |
|
|
2
Enanta Pharmaceuticals
ENTA
$366M
| $60.2M | 15.36% |
519,035
-220,703
| -30% | -$22M |
|
|
3
Amgen
AMGN
$208B
| $45M | 11.5% |
243,986
-17,434
| -7% | -$3.08M |
|
|
4
McKesson
MCK
$100B
| $43.3M | 11.05% |
324,243
+32,851
| +11% | +$4.8M |
|
|
5
Gilead Sciences
GILD
$162B
| $37.8M | 9.64% |
533,069
+11,066
| +2% | +$781K |
|
6
Merck
MRK
$322B
| $31.3M | 7.99% |
540,169
-38,593
| -7% | -$2.18M |
|
|
SHPG
7
DELISTED
Shire pic
SHPG
| $24.1M | 6.15% |
142,758
+22,758
| +19% | +$3.67M |
|
|
SRGA
8
DELISTED
Surgalign Holdings, Inc. Common Stock
SRGA
| $20.5M | 5.25% |
148,850
+3,457
| +2% | +$476K |
|
|
IVC
9
DELISTED
Invacare Corporation
IVC
| $19.7M | 5.04% |
1,061,615
-53,043
| -5% | -$960K |
|
|
10
Orthofix Medical
OFIX
$477M
| $17M | 4.35% |
300,049
+32,997
| +12% | +$1.88M |
|
|
AVNS
11
DELISTED
Avanos Medical
AVNS
| $10.4M | 2.67% |
182,502
-218,898
| -55% | -$11.6M |
|
|
JNP
12
DELISTED
Juniper Pharmaceuticals, Inc. Common Stock
JNP
| $2.68M | 0.69% |
308,478
-24,360
| -7% | -$219K |
|
|
STRR
13
DELISTED
Star Equity Holdings
STRR
| $516K | 0.13% |
6,657
-470
| -7% | -$37.6K |
|
|
14
CONMED
CNMD
$1.39B
| – | – |
-163,924
| Closed | -$10.4M |
|
|
VXRT
15
DELISTED
Vaxart
VXRT
| – | – |
-256,973
| Closed | -$1.37M |
|
Similar funds
CIA
2
CIM
JFG
PIP
LRIC
GAMC
TIA
Krensavage Asset Management's Q2 2018 Portfolio in Review
As of Q2 2018, Krensavage Asset Management held 16 positions worth $392M, down 5% from $412M the previous quarter. Its ten largest holdings account for 92% of the portfolio.
Krensavage Asset Management withdrew a net $51.4M in Q2 2018, closing 2 positions and reducing 9 holdings. Its most notable exit was CONMED, an estimated $10.4M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 91% of assets, down from 91% a quarter earlier.
Against the trend, Krensavage Asset Management added an estimated $4.8M to McKesson.
- Krensavage Asset Management added most to McKesson in Q2 2018, an estimated $4.8M increase.
- Krensavage Asset Management's biggest Q2 2018 reduction was Enanta Pharmaceuticals, cutting an estimated $22M.
- Krensavage Asset Management fully exited CONMED in Q2 2018, selling an estimated $10.4M.
- Krensavage Asset Management's ten largest holdings make up 92% of its $392M portfolio in Q2 2018.
- Krensavage Asset Management opened 0 new positions and closed 2 in Q2 2018.
- Krensavage Asset Management's portfolio value fell 5% quarter-over-quarter to $392M.
Based on Krensavage Asset Management's 13F filing for Q2 2018, filed 13 Aug 2018.